Terje Risberg
University of Tromsø
45 Papers
362 Citations
Terje Risberg is an academic researcher from University of Tromsø. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 21, co-authored 45 publications. Previous affiliations of Terje Risberg include Stavanger University Hospital & University Hospital of North Norway.
Chat about Author
Papers
Cancer patients use of nonproven therapy: a 5-year follow-up study.
TL;DR: The results demonstrate that cross-sectionally designed studies will underestimate the number of ever-users of NPT in a cancer patient population and do not influence observed survival among cancer patients seen in north Norway.
151
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
Ranjan Chrisanthar,Ranjan Chrisanthar,Stian Knappskog,Stian Knappskog,Erik Løkkevik,Gun Anker,Gun Anker,Bjørn Østenstad,Steinar Lundgren,Elisabet Ognedal Berge,Terje Risberg,Ingvil Mjaaland,Lovise Maehle,Lars Fredrik Engebretsen,Johan R. Lillehaug,Per Eystein Lønning,Per Eystein Lønning +16 more
TL;DR: This study is the first reporting an association between CHEK2 mutations and therapy resistance in human cancers and to document mutations in two genes acting direct up/down-stream to each other to cause therapy failure, emphasizing the need to investigate functional cascades in future studies.
Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
Trygve Lofterød,Elin Synnøve Mortensen,Hawa Nalwoga,Tom Wilsgaard,Hanne Frydenberg,Terje Risberg,Anne Elise Eggen,Anne McTiernan,Sura Mohammed Aziz,Erik Wist,Andreas Stensvold,Jon Brinchmann Reitan,Lars A. Akslen,Lars A. Akslen,Inger Thune +14 more
TL;DR: This study suggests that pre-diagnostic triglycerides and the HDL-cholesterol/total-ch cholesterol ratio may independently provide unique information regarding prognostic outcome among triple negative breast cancer patients.
Does use of alternative medicine predict survival from cancer
TL;DR: The use of AM seems to predict a shorter survival from cancer, and the effect appears predominantly in patients with a good PS, when compared with an ECOG PS of 1 or higher.
82
Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer
Bjørn Naume,Marit Synnestvedt,Ragnhild Sørum Falk,Gro Wiedswang,Kjetil Weyde,Terje Risberg,Christian Kersten,Ingvil Mjaaland,Lise Vindi,H. Sommer,Anna Barbro Sætersdal,Maria Christine Rypdal,Cecilie Bendigtsen Schirmer,Erik Wist,Elin Borgen +14 more
TL;DR: DTC status identifies high-risk patients after FEC chemotherapy, and DTC monitoring status after secondary treatment with docetaxel correlated strongly with survival, emphasizing the potential for DTC analysis as a surrogate marker for adjuvant treatment effect in breast cancer.
77